NVZMF:OTO-Novozymes A/S (USD)

COMMON STOCK | Specialty Chemicals | OTC Pink

Last Closing

USD 60.82

Change

+1.03 (+1.72)%

Market Cap

USD 11.39B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novozymes A/S is a biotech company. The Company is engaged in research, development, production and selling enzymes and microorganisms.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap
AIQUF L'Air Liquide S.A

-2.66 (-1.46%)

USD 106.63B
AIQUY Air Liquide SA ADR

-0.42 (-1.15%)

USD 106.62B
GVDBF Givaudan SA

N/A

USD 48.08B
SKFOF Sika AG

-5.63 (-2.02%)

USD 46.78B
SXYAY Sika AG ADR

-0.50 (-1.76%)

USD 45.85B
GVDNY Givaudan SA ADR

-0.61 (-0.63%)

USD 44.98B
DSMFF DSM-Firmenich AG

N/A

USD 33.23B
EMSHF EMS-CHEMIE HOLDING AG

N/A

USD 18.45B
SYIEF Symrise AG

N/A

USD 18.31B
NPPHY Nippon Paint Holdings Co. Ltd.

+0.05 (+1.20%)

USD 16.30B

ETFs Containing NVZMF

MVAE:PA 0.74 % 0.00 %

N/A

N/A
MVAE:LSE 0.00 % 0.00 %

N/A

N/A
MVEX:LSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Specialty Chemicals) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.60% 76% C+ 66% D+
Dividend Return 0.52% 9% A- 10% F
Total Return 11.12% 75% C 66% D+
Trailing 12 Months  
Capital Gain 16.11% 75% C 74% C
Dividend Return 0.55% 2% F 6% D-
Total Return 16.66% 74% C 72% C
Trailing 5 Years  
Capital Gain 26.66% 72% C 74% C
Dividend Return 15.63% 76% C+ 52% F
Total Return 42.28% 74% C 74% C
Average Annual (5 Year Horizon)  
Capital Gain 4.53% 44% F 48% F
Dividend Return 7.20% 44% F 47% F
Total Return 2.67% 58% F 51% F
Risk Return Profile  
Volatility (Standard Deviation) 24.11% 82% B 80% B-
Risk Adjusted Return 29.87% 62% D 66% D+
Market Capitalization 11.39B 94% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector